Kymera Therapeutics, Inc.
KYMRNASDAQHealthcareBiotechnology
As of Oct 22, 2026 close
- Market cap
- $10.88B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $55.26$130.05
- Volume (live)
- -
- Avg. volume (3M)
- 842.37K
Kymera Therapeutics (KYMR) Stock Price & Financial Analysis
Kymera Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $110.13 - $113.74 |
|---|---|
| 52-Week High | $130.05 |
| 52-Week Low | $55.26 |
| Open | $111.43 |
| Volume (last close) | 850.25K |
| Average Volume (3M) | 842.37K |
| Revenue (TTM) | 105.00M |
|---|---|
| Net Income (TTM) | -299.60M |
| Free Cash Flow (TTM) | -237.96M |
| EPS (TTM) | −$3.21 |
| Profit Margin | -285.34% |
| Operating Margin | -329.83% |
| Return on Equity (ROE) | -19.85% |
| Debt to Equity | 0.05 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 10.88B |
|---|---|
| Shares Outstanding | 98.18M |
| Price to Sales (P/S) | 103.65 |
| Price to Book (P/B) | 7.21 |
| EV/EBITDA | -35.70 |
| 50-Day MA | $115.09 |
|---|---|
| 200-Day MA | $94.70 |
| 1-Year Change | +91.91% |
Source: Market prices and company fundamentals. Data as of Oct 22, 2026. Data sources and methodology
Kymera Therapeutics at a Glance
As of the Oct 22, 2026 close, Kymera Therapeutics (KYMR) has a market capitalization of $10.88B. The stock trades at 103.7× sales. Over the trailing twelve months it lost $299.60M on revenue of $105.00M and burned $237.96M of free cash flow. Revenue grew 134.8% year over year.
As of its latest reported balance sheet, it holds $124.48M in cash and securities against $82.22M of debt, a net cash position of $42.26M.
Kymera Therapeutics does not currently pay a dividend.
The share price is up 91.9% over the past year. At $110.85 (the Oct 22, 2026 close) it sits within its 52-week range of $55.26 to $130.05, above its 200-day moving average of $94.70.
Based on 10 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $147.90, 33.4% above the Oct 22, 2026 close.
Frequently Asked Questions About Kymera Therapeutics
What is the current stock price for KYMR?
As of the Oct 22, 2026 close, KYMR stock trades at $110.85. The 52-week range is $55.26–$130.05, with a day range of $110.13–$113.74.
What is the P/E ratio for KYMR?
The P/E ratio (Price-to-Earnings) for KYMR is shown in the Key Statistics section. This valuation metric helps compare Kymera Therapeutics, Inc. to industry peers.
Does KYMR pay dividends?
Kymera Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for KYMR?
Based on ratings from 10 professional analysts over the last 90 days, the consensus for KYMR is Buy. The average 12-month price target is $147.90, a 33.4% upside from the Oct 22, 2026 close of $110.85.
What is the market cap of KYMR?
As of the Oct 22, 2026 close, Kymera Therapeutics's market capitalization is $10.88B, classifying it as a large-cap company. Kymera Therapeutics operates in the Healthcare sector within the Biotechnology industry.